Our Pipeline

Differentiated and versatile innate cell engagers to target hematological and solid tumors

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Innate Cell Engagers

AFM13

Disease Target CD30Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Phase 1
Hodgkin lymphoma
Phase 2
Hodgkin lymphoma + adoptive NK cells
Pre-IND
CD30-positive lymphoma
Phase 2

AFM24

Disease Target EGFRwtImmune Cell Target CD16A
Solid tumors
Pre-IND

AFM26

Disease Target BCMAImmune Cell Target CD16A
Multiple Myeloma
Pre-IND
Affimed programs
Partnered programs
Licensed programs

T Cell Engagers

AFM11

Disease Target CD19Immune Cell Target CD3
Acute lymphocytic leukemia
Phase 1

AMV564 (Amphivena)

Disease Target CD33Immune Cell Target CD3
Acute myeloid leukemia
Phase 1
Affimed programs
Partnered programs
Licensed programs

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay